stockrow
Saturday 7 November 2026
Export SABS’s income statement to Excel — free account
SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023.
- Revenue
- −91.0%
- EPS
- +74.3%
- Free cash flow
- −59.8%
- Total debt
- −5.01%
Quarter to June 2026, against a year earlier
3.03
0.09
+3.06%
Follow SABS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (34.27%) | (21.31%) | (14.45%) | (21.16%) |
+8 more TTM periods Free account |
|
| (28.97%) | (18.49%) | (11.81%) | (18.01%) | ||
ROIC |
(38.97%) | (29.58%) | (52.73%) | (47.07%) | |
Return on Tangible Assets |
(35.19%) | (22.69%) | (12.36%) | (18.48%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.72) | (0.99) | (2.37) | (3.53) | |
Free Cash Flow |
(57.44) | (53.16) | (45.71) | (37.59) | |
Capital Expenditures |
(3.50) | (1.91) | (0.93) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(17.92%) | (15.74%) | (18.20%) | (13.47%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(309.85) | (248.84) | (203.38) | (174.30) | |
Operating CF/Net income |
1.39 | 1.93 | 3.49 | 1.76 | |
Depreciation/Fixed assets |
0.21 | 0.22 | 0.22 | 0.23 | |
Capex/Depreciation |
(1.16) | (0.64) | (0.31) | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.68) | (0.96) | (2.32) | (3.52) | |
Capex per Share |
(0.04) | (0.04) | (0.05) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026